These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 17082013)

  • 1. The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure.
    Raab MS; Breitkreutz I; Hundemer M; Benner A; Klaus J; Hegenbart U; Moehler T; Ho AD; Zeier M; Goldschmidt H
    Haematologica; 2006 Nov; 91(11):1555-8. PubMed ID: 17082013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recovery of renal function after autologous stem cell transplantation in myeloma patients with end-stage renal failure.
    Tauro S; Clark FJ; Duncan N; Lipkin G; Richards N; Mahendra P
    Bone Marrow Transplant; 2002 Oct; 30(7):471-3. PubMed ID: 12368962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant.
    Lee CK; Zangari M; Barlogie B; Fassas A; van Rhee F; Thertulien R; Talamo G; Muwalla F; Anaissie E; Hollmig K; Tricot G
    Bone Marrow Transplant; 2004 Apr; 33(8):823-8. PubMed ID: 14767499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure.
    Knudsen LM; Nielsen B; Gimsing P; Geisler C
    Eur J Haematol; 2005 Jul; 75(1):27-33. PubMed ID: 15946307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study.
    Bird JM; Fuge R; Sirohi B; Apperley JF; Hunter A; Snowden J; Mahendra P; Milligan D; Byrne J; Littlewood T; Fegan C; McQuaker G; Pagliuca A; Johnson P; Rahemtulla A; Morris C; Marks DI;
    Br J Haematol; 2006 Aug; 134(4):385-90. PubMed ID: 16822294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study.
    Tricot G; Alberts DS; Johnson C; Roe DJ; Dorr RT; Bracy D; Vesole DH; Jagannath S; Meyers R; Barlogie B
    Clin Cancer Res; 1996 Jun; 2(6):947-52. PubMed ID: 9816255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermediate-dose (25mg/m2) IV melphalan for multiple myeloma with renal failure.
    Vigneau C; Ardiet C; Bret M; Laville M; Fiere D; Tranchand B; Fouque D
    J Nephrol; 2002; 15(6):684-9. PubMed ID: 12495285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis.
    Kumar SK; Dingli D; Lacy MQ; Dispenzieri A; Hayman SR; Buadi FK; Rajkumar SV; Litzow MR; Gertz MA
    Am J Hematol; 2008 Aug; 83(8):614-7. PubMed ID: 18429054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma.
    Qazilbash MH; Saliba RM; Hosing C; Mendoza F; Qureshi SR; Weber DM; Wang M; Flosser T; Couriel DR; De Lima M; Kebriaei P; Popat U; Alousi AM; Champlin RE; Giralt SA
    Bone Marrow Transplant; 2007 Mar; 39(5):279-83. PubMed ID: 17262062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.
    Leung N; Dispenzieri A; Fervenza FC; Lacy MQ; Villicana R; Cavalcante JL; Gertz MA
    Am J Kidney Dis; 2005 Aug; 46(2):270-7. PubMed ID: 16112045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
    Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA
    Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose chemotherapy with autologous stem cell transplantation for multiple myeloma: what predicts the outcome? Experience from a developing country.
    Kumar L; Ghosh J; Ganessan P; Gupta A; Hariprasad R; Kochupillai V
    Bone Marrow Transplant; 2009 Mar; 43(6):481-9. PubMed ID: 18978818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcome of autologous stem cell transplantation in light chain deposition disease.
    Lorenz EC; Gertz MA; Fervenza FC; Dispenzieri A; Lacy MQ; Hayman SR; Gastineau DA; Leung N
    Nephrol Dial Transplant; 2008 Jun; 23(6):2052-7. PubMed ID: 18178602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.
    Carreras E; Rosiñol L; Terol MJ; Alegre A; de Arriba F; García-Laraña J; Bello JL; García R; León A; Martínez R; Peñarrubia MJ; Poderós C; Ribas P; Ribera JM; San Miguel J; Bladé J; Lahuerta JJ;
    Biol Blood Marrow Transplant; 2007 Dec; 13(12):1448-54. PubMed ID: 18022574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple myeloma in end-stage renal disease.
    Penfield JG
    Semin Dial; 2006; 19(4):329-34. PubMed ID: 16893412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment and survival of multiple myeloma patients on programmed hemodialysis].
    Rekhtina IG; Ryzhko VV; Chavynchak RB; Biriukova LS
    Ter Arkh; 2007; 79(8):9-13. PubMed ID: 17926463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous peripheral blood stem cell transplantation in multiple myeloma using oral versus I.V. melphalan.
    Vela-Ojeda J; García-Ruiz-Esparza MA; Padilla-González Y; Gómez-Almaguer D; Gutiérrez-Aguirre CH; Gómez-Rangel D; Morales-Toquero A; Ruiz-Delgado GJ; Delgado-Lamas JL; Ruiz-Argüelles GJ
    Ann Hematol; 2007 Apr; 86(4):277-82. PubMed ID: 17262193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes.
    Christoforidou AV; Saliba RM; Williams P; Qazilbash M; Roden L; Aleman A; Weber D; Mendoza F; Podoloff D; Wendt R; Breitz H; Alexanian R; Champlin R; Giralt S
    Biol Blood Marrow Transplant; 2007 May; 13(5):543-9. PubMed ID: 17448913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-2-microglobulin level predicts outcome following autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
    Stella-Holowiecka B; Czerw T; Holowiecka-Goral A; Giebel S; Wojnar J; Holowiecki J
    Transplant Proc; 2007 Nov; 39(9):2893-7. PubMed ID: 18022010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
    Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.